Please use this identifier to cite or link to this item:
|Title:||Chronic obstructive pulmonary disease exacerbations : a hospital-based study|
Azzopardi, Lilian M.
|Keywords:||Lungs -- Diseases, Obstructive -- Treatment -- Malta|
Lungs -- Diseases, Obstructive -- Malta -- Case studies
Lungs -- Diseases, Obstructive -- Patients -- Medical care
Lungs -- Diseases, Obstructive -- Complications
|Publisher:||University of Malta. Department of Pharmacy|
|Citation:||Spiteri, J., Grech, L., Montefort, S., & Azzopardi, L. M. (2018, October). Chronic obstructive pulmonary disease exacerbations: a hospital-based study. Poster session presented at the 2018 ACCP Global Conference on Clinical Pharmacy, Seattle, Washington, USA.|
|Abstract:||A poster presentation regarding chronic obstructive pulmonary disease exacerbations: a hospital-based study. Introduction: The role of long-acting muscarinic antagonists (LAMAs) in chronic obstructive pulmonary disease (COPD) hospitalisation reduction has been established. The lack of availability of LAMAs on closed formularies hinders their use. Poor accessibility to LAMAs may have negative implications on healthcare expenditure and patients’ quality-of-life. Aims: To identify the hospitalisations due to COPD exacerbation and to estimate the resulting costs.|
|Appears in Collections:||Scholarly Works - FacM&SPha|
Files in This Item:
|Chronic_obstructive_pulmonary_disease_exacerbations_a_hospital_based_study_2018.pdf||577.76 kB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.